Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.8617 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von Nikita Menta und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Aprepitant, Drug Eruptions, ErbB Receptors, Morpholines. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Papulopustular eruptions are the most common dermatologic side effect of epidermal growth factor receptor inhibitor (EGFRI) therapy. Topical corticosteroids and oral tetracyclines are frequently used to manage these eruptions, though these treatments are limited by their adverse effects and efficacy. Results from preclinical studies suggest a role for topical aprepitant (HT-001) in the treatment of EGFRI-induced skin toxicities. Herein a case of EGFRI-induced papulopustular eruption with rapid treatment response to topical aprepitant (HT-001) 2% cream is described and the literature reviewed. J Drugs Dermatol. 2024;23(9):e173-e174. doi:10.36849/JDD.8617.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Menta, N., Vidal, S. I., & Friedman, A. (2024). Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8617
Vancouver
Menta N, Vidal SI, Friedman A. Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8617
BibTeX
@article{Menta2024,
author = {Menta, Nikita and Vidal, Savanna I and Friedman, Adam},
title = {Topical Aprepitant (HT-001): A Novel Therapy for Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.8617}
}
EUVIMED